Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
46 hedge funds and large institutions have $229M invested in Aratana Therapeutics, Inc. in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 3 closing their positions.
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
46% more capital invested
Capital invested by funds: $157M → $229M (+$72.1M)
44% more funds holding
Funds holding: 32 → 46 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$19.9M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$10.8M |
| 3 |
JP Morgan Chase
New York
|
+$6.17M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.58M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$2.16M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.94M |
| 3 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
-$1.23M |
| 4 |
Goldman Sachs
New York
|
-$661K |
| 5 |
KIA
Kopp Investment Advisors
Bloomington,
Minnesota
|
-$575K |
PETX Hedge Fund Activity: Q4 2013 in Review
46 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q4 2013, worth a combined $229M — up 46% from $157M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new PETX positions and 3 closed out — a net gain of 14 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Jennison Associates, adding an estimated $19.9M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.16M.
- 46 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q4 2013, up from 32 in Q3 2013.
- Funds reported $229M of Aratana Therapeutics, Inc. stock for Q4 2013, up 46% quarter-over-quarter.
- 17 funds opened new Aratana Therapeutics, Inc. positions in Q4 2013 and 3 closed out, a net change of +14 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q4 2013 was Jennison Associates, an estimated $19.9M added.
- The largest Aratana Therapeutics, Inc. seller in Q4 2013 was D.E. Shaw & Co, an estimated $2.16M sold.
Based on aggregated 13F filings for Q4 2013.